NASDAQ:CCXI

ChemoCentryx Stock Competitors

$16.57
+0.58 (+3.63 %)
(As of 09/17/2021 04:00 PM ET)
Add
Compare
Today's Range
$15.81
$16.75
50-Day Range
$13.53
$17.34
52-Week Range
$9.53
$70.29
Volume2.04 million shs
Average Volume2.07 million shs
Market Capitalization$1.16 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.46

ChemoCentryx (NASDAQ:CCXI) Vs. AMGN, GILD, REGN, VRTX, BIIB, and SGEN

Should you be buying ChemoCentryx stock or one of its competitors? The main competitors of ChemoCentryx include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), and Seagen (SGEN). These companies are all part of the "biotechnology" industry.

ChemoCentryx (NASDAQ:CCXI) and Amgen (NASDAQ:AMGN) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, profitability, valuation, dividends and earnings.

Valuation & Earnings

This table compares ChemoCentryx and Amgen's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ChemoCentryx$64.89 million17.85$-55,360,000.00($0.84)-19.73
Amgen$25.42 billion4.90$7.26 billion$16.6013.22

Amgen has higher revenue and earnings than ChemoCentryx. ChemoCentryx is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

63.2% of ChemoCentryx shares are owned by institutional investors. Comparatively, 74.7% of Amgen shares are owned by institutional investors. 8.0% of ChemoCentryx shares are owned by company insiders. Comparatively, 0.4% of Amgen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and recommmendations for ChemoCentryx and Amgen, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ChemoCentryx12502.50
Amgen291102.41

ChemoCentryx presently has a consensus target price of $37.8750, suggesting a potential upside of 128.58%. Amgen has a consensus target price of $249.4211, suggesting a potential upside of 13.69%. Given ChemoCentryx's stronger consensus rating and higher possible upside, equities research analysts plainly believe ChemoCentryx is more favorable than Amgen.

Volatility & Risk

ChemoCentryx has a beta of 1.46, suggesting that its stock price is 46% more volatile than the S&P 500. Comparatively, Amgen has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500.

Profitability

This table compares ChemoCentryx and Amgen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ChemoCentryx-568.54%-33.17%-24.34%
Amgen22.55%99.85%15.16%

Summary

Amgen beats ChemoCentryx on 9 of the 14 factors compared between the two stocks.

Gilead Sciences (NASDAQ:GILD) and ChemoCentryx (NASDAQ:CCXI) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, analyst recommendations and earnings.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Gilead Sciences and ChemoCentryx, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gilead Sciences071002.59
ChemoCentryx12502.50

Gilead Sciences presently has a consensus price target of $109.8750, suggesting a potential upside of 53.44%. ChemoCentryx has a consensus price target of $37.8750, suggesting a potential upside of 128.58%. Given ChemoCentryx's higher possible upside, analysts plainly believe ChemoCentryx is more favorable than Gilead Sciences.

Profitability

This table compares Gilead Sciences and ChemoCentryx's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gilead Sciences19.38%55.94%15.71%
ChemoCentryx-568.54%-33.17%-24.34%

Insider and Institutional Ownership

78.0% of Gilead Sciences shares are held by institutional investors. Comparatively, 63.2% of ChemoCentryx shares are held by institutional investors. 0.1% of Gilead Sciences shares are held by insiders. Comparatively, 8.0% of ChemoCentryx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Gilead Sciences and ChemoCentryx's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gilead Sciences$24.69 billion3.64$123 million$7.0910.10
ChemoCentryx$64.89 million17.85$-55,360,000.00($0.84)-19.73

Gilead Sciences has higher revenue and earnings than ChemoCentryx. ChemoCentryx is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Gilead Sciences has a beta of 0.39, meaning that its stock price is 61% less volatile than the S&P 500. Comparatively, ChemoCentryx has a beta of 1.46, meaning that its stock price is 46% more volatile than the S&P 500.

Summary

Gilead Sciences beats ChemoCentryx on 10 of the 14 factors compared between the two stocks.

ChemoCentryx (NASDAQ:CCXI) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership and risk.

Volatility and Risk

ChemoCentryx has a beta of 1.46, suggesting that its share price is 46% more volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.16, suggesting that its share price is 84% less volatile than the S&P 500.

Valuation & Earnings

This table compares ChemoCentryx and Regeneron Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ChemoCentryx$64.89 million17.85$-55,360,000.00($0.84)-19.73
Regeneron Pharmaceuticals$8.50 billion8.21$3.51 billion$28.6622.75

Regeneron Pharmaceuticals has higher revenue and earnings than ChemoCentryx. ChemoCentryx is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares ChemoCentryx and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ChemoCentryx-568.54%-33.17%-24.34%
Regeneron Pharmaceuticals50.11%50.43%33.56%

Analyst Recommendations

This is a breakdown of recent ratings and price targets for ChemoCentryx and Regeneron Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ChemoCentryx12502.50
Regeneron Pharmaceuticals041302.76

ChemoCentryx presently has a consensus price target of $37.8750, suggesting a potential upside of 128.58%. Regeneron Pharmaceuticals has a consensus price target of $698.3750, suggesting a potential upside of 7.13%. Given ChemoCentryx's higher probable upside, research analysts plainly believe ChemoCentryx is more favorable than Regeneron Pharmaceuticals.

Institutional and Insider Ownership

63.2% of ChemoCentryx shares are owned by institutional investors. Comparatively, 82.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. 8.0% of ChemoCentryx shares are owned by company insiders. Comparatively, 11.8% of Regeneron Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Regeneron Pharmaceuticals beats ChemoCentryx on 11 of the 14 factors compared between the two stocks.

ChemoCentryx (NASDAQ:CCXI) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, dividends, profitability, earnings and valuation.

Insider & Institutional Ownership

63.2% of ChemoCentryx shares are owned by institutional investors. Comparatively, 88.6% of Vertex Pharmaceuticals shares are owned by institutional investors. 8.0% of ChemoCentryx shares are owned by company insiders. Comparatively, 0.7% of Vertex Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares ChemoCentryx and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ChemoCentryx-568.54%-33.17%-24.34%
Vertex Pharmaceuticals29.80%29.73%21.96%

Analyst Ratings

This is a summary of recent ratings and target prices for ChemoCentryx and Vertex Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ChemoCentryx12502.50
Vertex Pharmaceuticals251602.61

ChemoCentryx presently has a consensus price target of $37.8750, indicating a potential upside of 128.58%. Vertex Pharmaceuticals has a consensus price target of $266.6111, indicating a potential upside of 41.59%. Given ChemoCentryx's higher probable upside, equities analysts clearly believe ChemoCentryx is more favorable than Vertex Pharmaceuticals.

Volatility & Risk

ChemoCentryx has a beta of 1.46, indicating that its share price is 46% more volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.63, indicating that its share price is 37% less volatile than the S&P 500.

Earnings and Valuation

This table compares ChemoCentryx and Vertex Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ChemoCentryx$64.89 million17.85$-55,360,000.00($0.84)-19.73
Vertex Pharmaceuticals$6.21 billion7.87$2.71 billion$9.0320.85

Vertex Pharmaceuticals has higher revenue and earnings than ChemoCentryx. ChemoCentryx is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Vertex Pharmaceuticals beats ChemoCentryx on 10 of the 14 factors compared between the two stocks.

Biogen (NASDAQ:BIIB) and ChemoCentryx (NASDAQ:CCXI) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, valuation, risk, analyst recommendations and earnings.

Institutional and Insider Ownership

83.2% of Biogen shares are held by institutional investors. Comparatively, 63.2% of ChemoCentryx shares are held by institutional investors. 0.6% of Biogen shares are held by insiders. Comparatively, 8.0% of ChemoCentryx shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Biogen and ChemoCentryx's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Biogen16.40%34.74%15.37%
ChemoCentryx-568.54%-33.17%-24.34%

Risk and Volatility

Biogen has a beta of 0.41, indicating that its stock price is 59% less volatile than the S&P 500. Comparatively, ChemoCentryx has a beta of 1.46, indicating that its stock price is 46% more volatile than the S&P 500.

Earnings & Valuation

This table compares Biogen and ChemoCentryx's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biogen$13.44 billion3.33$4.00 billion$33.708.91
ChemoCentryx$64.89 million17.85$-55,360,000.00($0.84)-19.73

Biogen has higher revenue and earnings than ChemoCentryx. ChemoCentryx is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Biogen and ChemoCentryx, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Biogen0131602.55
ChemoCentryx12502.50

Biogen presently has a consensus target price of $393.3573, indicating a potential upside of 31.04%. ChemoCentryx has a consensus target price of $37.8750, indicating a potential upside of 128.58%. Given ChemoCentryx's higher possible upside, analysts clearly believe ChemoCentryx is more favorable than Biogen.

Summary

Biogen beats ChemoCentryx on 10 of the 14 factors compared between the two stocks.

Seagen (NASDAQ:SGEN) and ChemoCentryx (NASDAQ:CCXI) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

Institutional & Insider Ownership

88.2% of Seagen shares are owned by institutional investors. Comparatively, 63.2% of ChemoCentryx shares are owned by institutional investors. 27.6% of Seagen shares are owned by company insiders. Comparatively, 8.0% of ChemoCentryx shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Seagen and ChemoCentryx's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Seagen25.06%19.02%16.03%
ChemoCentryx-568.54%-33.17%-24.34%

Valuation & Earnings

This table compares Seagen and ChemoCentryx's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Seagen$2.18 billion13.06$613.67 million$3.3047.34
ChemoCentryx$64.89 million17.85$-55,360,000.00($0.84)-19.73

Seagen has higher revenue and earnings than ChemoCentryx. ChemoCentryx is trading at a lower price-to-earnings ratio than Seagen, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Seagen has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500. Comparatively, ChemoCentryx has a beta of 1.46, suggesting that its stock price is 46% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings for Seagen and ChemoCentryx, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Seagen06802.57
ChemoCentryx12502.50

Seagen presently has a consensus target price of $184.75, indicating a potential upside of 18.27%. ChemoCentryx has a consensus target price of $37.8750, indicating a potential upside of 128.58%. Given ChemoCentryx's higher probable upside, analysts plainly believe ChemoCentryx is more favorable than Seagen.

Summary

Seagen beats ChemoCentryx on 11 of the 14 factors compared between the two stocks.

pixel
Ad Investorplace Media
Expert Says New Battery Could Be "Tesla Killer"
Tech Futurist who uncovered Tesla says: New “Forever Battery” is here and it is disrupting the $3 trillion EV Revolution in 2021.

ChemoCentryx Competitors List

Competitor NameBTM RankShare PriceAnalysts' Price TargetMarket CapRevenueP/E RatioEmployee CountIndicator(s)
Amgen logo
AMGN
Amgen
2.8$219.38
+0.9%
$249.42
+13.7%
$124.58 billion$25.42 billion22.3224,300Analyst Report
High Trading Volume
Gilead Sciences logo
GILD
Gilead Sciences
3.4$71.61
+0.4%
$75.53
+5.5%
$89.79 billion$24.69 billion17.4713,600Ex-Dividend
News Coverage
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.5$651.88
+0.2%
$698.38
+7.1%
$69.72 billion$8.50 billion11.719,123Analyst Report
Insider Selling
Analyst Revision
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.8$188.30
+0.6%
$266.61
+41.6%
$48.85 billion$6.21 billion24.843,400
Biogen logo
BIIB
Biogen
2.5$300.19
+0.2%
$393.36
+31.0%
$44.74 billion$13.44 billion24.099,100Analyst Report
News Coverage
Seagen logo
SGEN
Seagen
2.3$156.21
+1.7%
$184.75
+18.3%
$28.42 billion$2.18 billion47.922,092
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
2.1$190.34
+0.1%
$169.33
+11.0%
$22.62 billion$492.85 million-25.081,453
Exact Sciences logo
EXAS
Exact Sciences
2.5$108.15
+5.0%
$151.06
+39.7%
$18.60 billion$1.49 billion-19.815,000Gap Down
Novavax logo
NVAX
Novavax
1.7$237.54
+0.1%
$249.60
+5.1%
$17.69 billion$475.60 million-17.33791Insider Selling
Repligen logo
RGEN
Repligen
2.0$306.90
+2.3%
$259.50
+15.4%
$16.85 billion$366.26 million171.451,128Analyst Report
Analyst Revision
News Coverage
High Trading Volume
Incyte logo
INCY
Incyte
2.7$75.99
+1.3%
$92.29
+21.4%
$16.78 billion$2.67 billion49.991,773High Trading Volume
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
2.7$77.76
+1.6%
$103.24
+32.8%
$14.26 billion$1.86 billion18.133,059Analyst Report
High Trading Volume
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$96.50
+0.8%
$119.31
+23.6%
$9.12 billion$1.05 billion25.94845
United Therapeutics logo
UTHR
United Therapeutics
2.5$200.08
+2.5%
$224.38
+12.1%
$8.99 billion$1.48 billion19.44950Insider Selling
Short Interest ↑
Gap Up
Exelixis logo
EXEL
Exelixis
2.7$20.72
+0.9%
$34.50
+66.5%
$6.53 billion$987.54 million71.45773Insider Selling
News Coverage
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
2.5$42.04
+0.0%
$54.14
+28.8%
$5.98 billion$267.59 million26.95288High Trading Volume
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
2.1$37.21
+2.1%
$54.75
+47.1%
$5.25 billion$729 million-9.61757High Trading Volume
Alkermes logo
ALKS
Alkermes
1.9$30.11
+1.1%
$28.25
+6.2%
$4.86 billion$1.04 billion-75.272,245High Trading Volume
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
2.4$61.05
+1.8%
$97.25
+59.3%
$3.73 billion$320,000.00-7.47363
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.3$57.14
+0.6%
$96.50
+68.9%
$3.07 billion$1.56 billion10.312,200
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
2.1$11.00
+0.7%
$18.73
+70.2%
$2.93 billion$260.89 million-11.46483Insider Selling
News Coverage
High Trading Volume
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
2.0$15.70
+3.1%
$19.45
+23.9%
$2.81 billion$17.81 million-13.08246Analyst Report
Insider Selling
News Coverage
OPKO Health logo
OPK
OPKO Health
2.3$3.94
+3.0%
$6.50
+65.0%
$2.68 billion$1.44 billion35.825,269Insider Buying
Myriad Genetics logo
MYGN
Myriad Genetics
1.5$33.72
+3.3%
$25.33
+24.9%
$2.63 billion$638.60 million-24.612,700Gap Down
Celldex Therapeutics logo
CLDX
Celldex Therapeutics
2.0$54.39
+2.0%
$57.25
+5.3%
$2.53 billion$7.42 million-32.57124Analyst Report
Analyst Revision
News Coverage
Gap Up
High Trading Volume
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
2.2$144.73
+6.7%
$226.25
+56.3%
$2.41 billion$186.42 million52.252,018Analyst Report
Gap Down
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.8$12.35
+2.2%
$12.00
+2.8%
$2.01 billion$389.52 million3.96232Gap Down
Dynavax Technologies logo
DVAX
Dynavax Technologies
2.3$14.89
+3.0%
$21.00
+41.0%
$1.71 billion$46.55 million-57.27245Analyst Report
Analyst Revision
News Coverage
Codexis logo
CDXS
Codexis
1.7$25.58
+3.8%
$30.25
+18.3%
$1.65 billion$69.06 million-69.13181
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.7$9.55
+3.4%
$23.00
+140.8%
$1.39 billion$118.19 million-10.05413News Coverage
Gap Down
Agenus logo
AGEN
Agenus
2.0$5.83
+4.5%
$10.00
+71.5%
$1.36 billion$88.17 million-5.21359Insider Selling
News Coverage
Gap Up
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
2.4$81.74
+1.9%
$172.13
+110.6%
$1.36 billionN/A-5.5942News Coverage
High Trading Volume
ImmunoGen logo
IMGN
ImmunoGen
1.9$5.80
+2.1%
$10.10
+74.1%
$1.17 billion$132.30 million-20.0079High Trading Volume
MannKind logo
MNKD
MannKind
2.1$4.53
+0.7%
$6.20
+36.9%
$1.13 billion$65.14 million-12.94241
Innoviva logo
INVA
Innoviva
1.3$15.65
+2.6%
$10.00
+36.1%
$1.09 billion$336.79 million6.315Gap Down
High Trading Volume
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.7$16.95
+4.1%
$18.00
+6.2%
$943.06 million$248.17 million29.22292Insider Selling
News Coverage
Gap Down
High Trading Volume
Curis logo
CRIS
Curis
2.0$8.48
+1.1%
$21.00
+147.6%
$776.73 million$10.84 million-18.8428
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
2.2$4.86
+5.8%
$12.00
+146.9%
$702.14 million$24 million12.4678Gap Down
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
2.0$3.90
+1.8%
$11.00
+182.1%
$666.32 million$108.62 million-78.00169News Coverage
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
2.0$15.29
+2.3%
$40.50
+164.9%
$581.83 million$230,000.00-0.6965Short Interest ↑
News Coverage
High Trading Volume
Clovis Oncology logo
CLVS
Clovis Oncology
1.8$4.84
+4.8%
$6.00
+24.0%
$573.10 million$164.52 million-1.53N/A
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
2.3$15.93
+3.3%
$33.00
+107.2%
$528.89 million$312.69 million-3.10498Gap Down
Verastem logo
VSTM
Verastem
1.9$2.76
+2.2%
$6.33
+129.5%
$498.89 million$88.52 million-12.0049High Trading Volume
Geron logo
GERN
Geron
1.1$1.41
+0.7%
N/A$452.05 million$250,000.00-4.5554
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
2.3$2.43
+4.1%
$9.00
+270.4%
$398.70 million$109.33 million-1.98176Gap Down
High Trading Volume
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
2.1$1.82
+7.1%
$3.83
+110.6%
$392.32 million$150,000.00-4.33105Gap Down
High Trading Volume
Arctos NorthStar Acquisition logo
ANAC
Arctos NorthStar Acquisition
1.2$9.77
+0.1%
N/A$386.21 millionN/A0.00N/A
Fortress Biotech logo
FBIO
Fortress Biotech
2.1$3.35
+2.1%
$10.60
+216.4%
$338.56 million$45.60 million-8.17111News Coverage
Molecular Templates logo
MTEM
Molecular Templates
2.6$5.99
+3.5%
$14.50
+142.1%
$336.29 million$18.84 million-3.27239News Coverage
Gap Up
High Trading Volume
Infinity Pharmaceuticals logo
INFI
Infinity Pharmaceuticals
1.6$3.63
+5.8%
$9.63
+165.2%
$322.05 million$1.72 million-5.9523Gap Down
This page was last updated on 9/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.